Your session is about to expire
← Back to Search
Timely Nudge About Lab Results to Increase myGeisinger Uptake
N/A
Waitlist Available
Led By Amir Goren, PhD
Research Sponsored by Geisinger Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month post-intervention
Awards & highlights
No Placebo-Only Group
Summary
The purpose of the current study is to test whether sending email communications in a timely manner - when patients have laboratory results available to view on the myGeisinger patient portal - increases enrollment in the portal.
Eligible Conditions
- Telemedicine
- Health Behaviors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month post-intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month post-intervention
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Email Opened - Email Including a "Get Started" Button vs. a "View Results" Button
Enrollment - Email Including a "Get Started" Button vs. a "View Results" Button
Enrollment - Timely Email (Combined Email Arms) vs. no Intervention
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Timely nudge - view resultsExperimental Treatment2 Interventions
Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a "View My Lab Results" button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page.
Group II: Timely nudge - get startedExperimental Treatment2 Interventions
Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a "Get Started With myGeisinger" button that is transparent about the next step in the process, before the patient can view test results.
Group III: ControlActive Control1 Intervention
Patients do not receive an email
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Timely
2020
N/A
~5020
Transparency
2020
N/A
~19660
Foot-in-the-door
2020
N/A
~5020
Find a Location
Who is running the clinical trial?
Geisinger ClinicLead Sponsor
155 Previous Clinical Trials
1,973,617 Total Patients Enrolled
Amir Goren, PhDPrincipal InvestigatorGeisinger Clinic
21 Previous Clinical Trials
528,831 Total Patients Enrolled